STAT3 and neoplasm: Nevertheless, although late-stage Stat3-deficient tumours failed to respond to an anti-CXCL1 monotherapy, the use of CXCL1 blockers combined with standard chemotherapy or as maintenance therapy could be a reasonable alternative to treat these tumours and it deserves further investigation.